<DOC>
	<DOCNO>NCT00166296</DOCNO>
	<brief_summary>The purpose study determine whether use antidepressant ( escitalopram ) prevent depressive episode appear treatment peg-interferon ribavirin patient chronic hepatitis C .</brief_summary>
	<brief_title>Efficacy Safety Escitalopram Prevention Depression Induced Peg-Interferon Hepatitis C Patients</brief_title>
	<detailed_description>Chronic hepatitis C prevalent condition , main cause chronic liver disease , include cirrhosis cancer . Nowadays , interferon-alfa combination ribavirin main treatment option condition . In last year , interferon molecule modify order improve tolerance pegylated interferon . Interferon-alfa associated high prevalence psychiatric side effect , especially major depression ( 25 % case ) , one main concern use treatment . In fact , major depression one main reason treatment withdrawal treatment failure . Major depression induce interferon-alfa successfully treated antidepressant , n't know antidepressant also prevent development major depression , safe intervention . In literature , one control trial issue , cancer patient , open study hepatitis C. In order evaluate efficacy , safety , antidepressant ( escitalopram ) prevent peginterferon 's induced depressive episode patient chronic hepatitis C , design 14-weeks placebo-controlled , double-blind , randomized clinical trial . Study intervention start two week peginterferon + ribavirin 's treatment onset . Subjects include study patient chronic hepatitis C go treat peginterferon-alfa2a + ribavirin , without mental disorder require active psychotropic treatment . The main variable study appearance major depressive episode , follow Diagnostic &amp; Statistical Manual Mental Disorders ( DSM-IV ) criterion , total score Montgomery-Asberg Depression Rating Scale , along three assessment point 4 , 8 12 week treatment interferon . There also follow-up period 6 month treatment interferon complete .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patients chronic hepatitis C go initiate treatment peginterferon alfa2a + ribavirin . Age 1865 year . Signed informed consent . If female , fertile period use barrier contraceptive . Patients able understand fill write questionnaire . Hepatic cirrhosis carcinoma . Less 4000/mm3 leucocyte , less 70000/mm3 platelet . Hemoglobin le 11 g/dL ( female ) 12 ( male ) . Any risk factor hemolysis . Comorbid severe medical condition ( kidney , immune system , lung , heart , thyroid , etc ) . Baseline mental disorder require antidepressant ( depressive disorder anxiety disorder ) . Other baseline mental disorder ( delirium , substance use disorder ) . Mental disorder time ( dementia , psychotic disorder , bipolar disorder . Contraindications escitalopram ( hypersensibility , diabetes , patient use serotoninergic agent , drug enhance risk bleeding , monoamineoxidase inhibitor MAOIs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Major depressive disorder , chemically induce .</keyword>
	<keyword>Peginterferon alfa-2a .</keyword>
	<keyword>Escitalopram .</keyword>
	<keyword>Chronic hepatitis C , psychology .</keyword>
	<keyword>Prophylactic treatment .</keyword>
</DOC>